Results 71 to 80 of about 306 (101)

Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults). [PDF]

Pituitary, 2021
Höybye C, Beck-Peccoz P, Murray RD, Simsek S, Stalla G, Strasburger CJ, Urosevic D, Zouater H, Johannsson G.   +8 more
europepmc   +1 more source

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. [PDF]

Biol Ther, 2014
Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.   +7 more
europepmc   +1 more source

The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries. [PDF]

BioDrugs, 2023
Klein K, Gencoglu M, Heisterberg J, Acha V, Stolk P.   +4 more
europepmc   +1 more source

Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study. [PDF]

Med Devices (Auckl), 2015
Partsch CJ, Schnabel D, Ehtisham S, Johnstone HC, Zabransky M, Kiess W.   +5 more
europepmc   +1 more source

Clinicians' Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19. [PDF]

Patient Prefer Adherence, 2021
Blair J, Warth K, Suvarna Y, Cappa M.
europepmc   +1 more source

Fármacos biológicos y biosimilares : aclarando conceptos [PDF]

, 2018
Asensio Ostos, Carmen, Rodriguez Cumplido, Dolores   +1 more
core   +1 more source

Long-term safety and efficacy of Omnitrope^® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. [PDF]

J Endocrinol Invest, 2017
Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P.   +11 more
europepmc   +1 more source

Experience of switching from a daily to a less frequent administration of injection treatments. [PDF]

PLoS One, 2022
Loftus J, Yaworsky A, Roland CL, Turner-Bowker D, McLafferty M, Su S, Lamoureux RE.   +6 more
europepmc   +1 more source

Erratum to: Long-term safety and efficacy of Omnitrope^® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. [PDF]

J Endocrinol Invest, 2017
Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P.   +11 more
europepmc   +1 more source

Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009 [PDF]

, 2010
Seamon, Matthew J
core   +1 more source